Transcript Document 7373639

Pneumonia
Dr Ibrahim Bashayreh, RN, PhD.
28/10/2009
1
Pneumonia
Acute inflammation of lung (lower
respiratory tract) caused by
microorganism, comes with fever,
focal chest symptoms, shadowing
on CXR
Leading cause of death until 1936
 Discovery
of sulfa drugs and
penicillin
28/10/2009
2
Classification

28/10/2009
Community Acquired Pneumonia
 Occur within 48 hrs of admission or in
patient’s who haven’t been hospitalized in the
last 2 wks
 Strep pneumonia, mycoplasma pneumonia,
influenza A, Haemophilus influenza, and
Legionella are more common pathogens
 Patients with chronic diseases are more prone
to Klebsiella and other gram negative
organisms
 Highest incidence in winter
 Smoking important risk factor
3
Types of Pneumonia
Hospital-acquired pneumonia (HAP) (Nasocomial Infection)







28/10/2009
Develops 2 or more days after admission
Gram negative bacilli (Klebsiella, Pseudomonas, E coli,
Proteus) or Staphylococcus are more common pathogens
Aspiration around an ETT/reduced consciousness or
difficulty swallowing allows pathogens in the oropharynx to
colonize the lungs
Ventilator-associated pneumonia (VAP): in patients on
ventilators
Aspiation: follows aspiration of gastric contents
Immunosuppression: chemotherapy/bone marrow
transplant/HIV patients susceptible to fungi and viral
infections as well as other pathogen
Highest mortality rate of nosocomial infections
4
Causes of HAP
 Pseudomonas
 Enterobacter
 S.
aureus
 S. pneumoniae
 Immunosuppressive therapy
 General debility
 Endotracheal intubation
28/10/2009
5
Aging, 65 years or older
Male
Children under 2
Having HIV or AIDS
Increased frequency of gram- negative bacilli
(leukemia, diabetes, alcoholism)
Smoking
Being around certain chemicals
Living in certain parts of the country
Being hospitalized in ICU & having ETT
Pollution
Malnutrition
28/10/2009
6
Acquisition of Organisms
Aspiration from nasopharynx,
oropharynx
Inhalation of microbes
Hematogenous spread from
primary infection elsewhere
28/10/2009
7
Signs & Symptoms
Symptoms
Dyspnea
 Pleurisy
 Cough
 Discolored sputum
Signs
 Cyanosis
 Tachycardia
 Tachypnea
 Dull percussion
 Crepitus
 Bronchial breath sounds
 Pleural rub
 Sweating, cold clammy skin
Non-respiratory features
 Confusion, fatigue
 Diarrhea, N&V.
28/10/2009
8
Clinical Manifestations
CAP symptoms
 Sudden
onset of fever
 Chills
 Cough
productive of purulent
sputum
 Pleuritic chest pain
28/10/2009
9
Pathophysiology:
Pneumococcal Pneumonia
Congestion from outpouring of
fluid into alveoli
 Microorganisms multiply
and spread
infection, interfering with lung
function
28/10/2009
10
Pathophysiology:
Pneumococcal Pneumonia
Red hepatization
 Massive
dilation of capillaries
 Alveoli fill with organisms,
neutrophils, RBCs, and fibrin
 Causes
lungs to appear red and
granular, similar to liver
28/10/2009
11
Complications
Pleurisy (pain with breathing)
Pleural effusion
 Usually
is sterile and reabsorbed in 1-2
weeks or requires thoracentesis
Atelectasis
 Usually
clears with cough and deep
breathing
28/10/2009
12
Complications
Delayed resolution
 Persistent
infection seen on x-ray as
residual consolidation
Lung abscess (pus-containing lesions)
Empyema (purulent exudate in pleural
cavity)
 Requires
antibiotics and drainage of
exudate
28/10/2009
13
Complications
Pericarditis
 From
spread of microorganism
Arthritis
 Systemic
spread of organism
 Exudate can be aspirated
Meningitis
 Patient
who is disoriented, confused, or
somnolent should have lumbar puncture
to evaluate meningitis
28/10/2009
14
Complications
Endocarditis
 Microorganisms
attack endocardium and
heart valves
 Manifestations similar to bacterial
endocarditis
28/10/2009
15
Diagnostic Tests
History
Physical exam
Chest x-ray
Gram stain of sputum
Sputum culture and sensitivity
Pulse oximetry or ABGs
CBC, differential, chems
Blood cultures
28/10/2009
16
Collaborative Care
Antibiotic therapy
Oxygen for hypoxemia
Analgesics for chest pain
Antipyretics
Influenza drugs
Influenza vaccine
Fluid intake at least 3 L per day
Caloric intake at least 1500 per day
28/10/2009
17
Collaborative Care
Pneumococcal vaccine
 Indicated for those at risk
 Chronic
illness such as heart and lung
disease, diabetes mellitus
 Recovering from severe illness
 65 or older
 In long-term care facility
28/10/2009
18
Nursing Assessment
History of Predisposing/Risk Factors
 Lung
cancer
 COPD
 Diabetes mellitus
 Debilitating disease
 Malnutrition
28/10/2009
19
Nursing Assessment
History of Predisposing/Risk Factors
 AIDS
 Use
of antibiotics, corticosteroids,
chemotherapy, immunosuppressants
 Recent abdominal or thoracic
surgery
 Smoking, alcoholism, respiratory
infections
 Prolonged bed rest
28/10/2009
20
Nursing Assessment
Clinical Manifestations
 Dyspnea
 Nasal congestion
 Pain with breathing
 Sore throat
 Muscle aches
 Fever
28/10/2009
21
Nursing Assessment
Clinical Manifestations
 Restlessness or lethargy
 Splinting affected area
 Tachypnea
 Asymmetric chest movements
 Use of accessory muscles
 Crackles
 Green or yellow sputum
28/10/2009
22
Nursing Assessment
Clinical Manifestations
 Tachycardia
 Changes in mental status
 Leukocytosis
 Abnormal ABGs
 Pleural effusion
 Pneumothorax on CXR
28/10/2009
23
Nursing Diagnoses
Ineffective breathing pattern
Ineffective airway clearance
Acute pain
Imbalanced nutrition: less than body
requirements
Activity intolerance
28/10/2009
24
Planning
Goals: Patient will have
 Clear
breath sounds
 Normal breathing patterns
 No signs of hypoxia
 Normal chest x-ray
 No complications related to pneumonia
28/10/2009
25
Nursing Implementation
Teach nutrition, hygiene, rest, regular
exercise to maintain natural resistance
Prompt treatment of URIs
28/10/2009
26
Nursing Implementation
Encourage those at risk to obtain
influenza and pneumococcal
vaccinations
Reposition patient q2h
Assist patients at risk for aspiration
with eating, drinking, and taking meds
28/10/2009
27
Nursing Implementation
Assist immobile patients with turning
and deep breathing
Strict asepsis
Emphasize need to take course of
medication(s)
Teach drug-drug interactions
28/10/2009
28
Evaluation
Dyspnea not present
SpO2 > 95
Free of adventitious breath sounds
Clears sputum from airway
28/10/2009
29
Evaluation
Reports pain controlled
Verbalizes causal factors
Adequate fluid and caloric intake
Performs ADLs
28/10/2009
30
Tuberculosis
Famous people who have had TB
Fredric Chopin*
Eleanor Roosevelt*
Nelson Mandela
Ringo Starr
Tom Jones
Tina Turner
*Died of TB
28/10/2009
31
What is tuberculosis (TB)?
Disease caused by bacteria called
Mycobacterium tuberculosis
Chronic bacterial infection
Was once the leading cause of death in US
The number of cases declined in the 1940’s
when drugs were developed to treat TB
TB is still a problem worldwide
 8 million people develop TB yearly
 3 million die
28/10/2009
32
Tuberculosis
5-10% become
active
Only contagious
when active
Primarily affect
lungs but…
 Kidneys
 Liver
 Brain
 Bone
28/10/2009
33
How is TB spread?
Through the air from person to
person by coughing
Usually attacks lungs
Two stages
 Latent TB
asymptomatic and not contagious
 can take medication to prevent development
of disease

 Active
TB Disease
May spread to others
 May have abnormal chest x-ray
 Usually have positive skin test

28/10/2009
34
Symptoms of TB
Chills
Fever
Weakness or fatigue
Sweating while sleeping, Night sweats
Cough that lasts longer than 2 weeks
Pain in chest
Coughing up blood or sputum
28/10/2009
35
Risk Factors
Close contact with someone who is infected
with TB
Traveling to a country where TB is common
Foreign-born individuals and minorities
have a higher incidence of developing TB
 2002: 50% of US cases were in foreignborn individuals.
 2002: 80% of all US TB cases were in
ethnic and racial minorities.
28/10/2009
36
Risk Factors
Immunocompromise
Substance abuse
Indigent (POVERTY)
Living in overcrowded, substandard housing
Health care workers performing high risk
activities
28/10/2009
37
Multi-drug resistant TB (MDR TB)
Bacteria become resistant to antibiotics
Arose from improper use of antibiotics in the
treatment of TB
Treatment of one case can cost up to $1.3 million
45 states and Washington, DC have confirmed cases
of MDR TB
Treatment is difficult and costly
Can develop from not taking proper course of
antibiotics for TB
MDR TB can be spread by an infected person
28/10/2009
38
How to protect yourself
BCG vaccine for TB is given in many countries
Not recommended for healthcare workers
unless a high percentage of patients are
infected with MDR TB
PPD test if exposure is suspected
USE proper PPE when in contact with patients
who may have TB
28/10/2009
39
PPD Skin Test Procedure
Intradermal administration of PPD
 L forearm
Must be “read” between 48 and 72 hours
To accurately “read”
 Visual inspection for erythema
 Tactile inspection to monitor size of
induration
 10 mm or > area of induration
28/10/2009
 Consider
positive and must be referred
40
Tuberculosis
Diagnostic exams
PPD
 Mantoux skin test
 > 10mm in diameter
 induration
 Indicates:
 Latent TB
 Read
 48-72 after
 Intradermal: 15-degrees
 Do not rub
28/10/2009
41
Confirmation of Disease
Positive reaction does not
necessarily mean active disease.
 May indicate exposure to TB
Diagnosis confirmed by:
 Positive smear for AFB and
 Sputum culture of
Mycobacterium tuberculosis
28/10/2009
42
Interventions
Combination drug
therapy
 Isoniazid
 Rifampicin
 Pyrazinamide
 Ethambutol or
streptomycin
Education
 Must follow
exact drug
regimen
 Proper
nutrition

Reverse weight
loss and lethargy
 About
28/10/2009
disease
43
Tuberculosis Treatment
INH
 Isonicotinyl Hydrazine
 Isoniazid
 Toxic to the liver
Rifampicin
 Turns urine red
Streptomycin
 Causes 8th cranial nerve
damage
 Acoustic nerve
28/10/2009
44
CLASSIFICATION
Class 0—no exposure
Class 1—exposure, no infection
Class 2—latent infection; no disease (positive
PPD but no evidence of active TB
Class 3—disease; clinically active
Class 4—disease; not clinically active
Class 5—suspected disease; diagnosis
pending
28/10/2009
45
MEDICAL MANAGEMENT
Treated with chemotherapeutic agents for 612 months
Resistance increasing. May be primary,
secondary, or multidrug resistant.
Primary—resistance to one of first line drugs
in those who have not had prior treatment
Secondary—resistance to one or more antiTB drugs in patients undergoing tx
Multidrug resistance—resistance to two
agents, INH and Rifampicin.
28/10/2009
46
Tuberculosis
Complications
Pleurisy
Pericarditis
Meningitis
Bone infections
Malnutrition
Drug-toxicity
28/10/2009
47
Tuberculosis
Nursing Dx
Impaired gas exchange
Ineffective airway clearance
Anxiety
Knowledge deficit
Alt. nutrition
28/10/2009
48
Tuberculosis
Preventative measures
Clean well ventilated living areas
Resp. isolation
Vaccine?
 BCG
 Does not prevent TB
 Causes a + PPD
If exposed take
 INH
28/10/2009
49
Tuberculosis Summary
Chronic bacterial infection
spread through the air
Fever, chills, sweating while
sleeping, persistent cough,
coughing up blood or sputum
Multi-drug-resistant tuberculosis
MDR TB
Use proper PPE and get PPD test
if exposed
28/10/2009
50